GENENTECH INC Company Profile
✉ Email this page to a colleague
What is the competitive landscape for GENENTECH INC, and when can generic versions of GENENTECH INC drugs launch?
GENENTECH INC has eight approved drugs.
There are fifty-six US patents protecting GENENTECH INC drugs.
There are eight hundred and sixty-one patent family members on GENENTECH INC drugs in fifty-four countries and sixty-eight supplementary protection certificates in nineteen countries.
Summary for GENENTECH INC
| International Patents: | 861 |
| US Patents: | 56 |
| Tradenames: | 5 |
| Ingredients: | 5 |
| NDAs: | 8 |
| Drug Master File Entries: | 7 |
| Patent Litigation for GENENTECH INC: | See patent lawsuits for GENENTECH INC |
Drugs and US Patents for GENENTECH INC
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genentech Inc | XOFLUZA | baloxavir marboxil | TABLET;ORAL | 210854-001 | Oct 24, 2018 | DISCN | Yes | No | 12,064,438 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Genentech Inc | ESBRIET | pirfenidone | TABLET;ORAL | 208780-003 | Jan 11, 2017 | AB | RX | Yes | Yes | 10,188,637 | ⤷ Sign Up | Y | ⤷ Sign Up | ||
| Genentech Inc | ESBRIET | pirfenidone | TABLET;ORAL | 208780-003 | Jan 11, 2017 | AB | RX | Yes | Yes | 8,084,475 | ⤷ Sign Up | ⤷ Sign Up | |||
| Genentech Inc | ESBRIET | pirfenidone | TABLET;ORAL | 208780-003 | Jan 11, 2017 | AB | RX | Yes | Yes | 8,592,462 | ⤷ Sign Up | ⤷ Sign Up | |||
| Genentech Inc | XOFLUZA | baloxavir marboxil | TABLET;ORAL | 210854-001 | Oct 24, 2018 | DISCN | Yes | No | 10,392,406 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for GENENTECH INC
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Genentech Inc | ESBRIET | pirfenidone | TABLET;ORAL | 208780-001 | Jan 11, 2017 | 9,561,217 | ⤷ Sign Up |
| Genentech Inc | ESBRIET | pirfenidone | TABLET;ORAL | 208780-002 | Jan 11, 2017 | 9,561,217 | ⤷ Sign Up |
| Genentech Inc | ESBRIET | pirfenidone | TABLET;ORAL | 208780-003 | Jan 11, 2017 | 9,561,217 | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for GENENTECH INC drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 267 mg, 534 mg and 801 mg | ➤ Subscribe | 2018-10-15 |
International Patents for GENENTECH INC Drugs
Supplementary Protection Certificates for GENENTECH INC Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1934174 | 2016/022 | Ireland | ⤷ Sign Up | PRODUCT NAME: COBIMETINIB, INCLUDING PHARMACEUTICALLY ACCEPTABLE SALTS AND SOLVATES, IN PARTICULAR COBIMETINIB HEMIFUMARATE.; REGISTRATION NO/DATE: EU/1/15/1048/001 20151120 |
| 3143025 | C03143025/01 | Switzerland | ⤷ Sign Up | PRODUCT NAME: RISDIPLAM; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 67251 06.05.2021 |
| 3143025 | 122021000051 | Germany | ⤷ Sign Up | PRODUCT NAME: RISDIPLAM ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/21/1531 20210326 |
| 1934174 | SPC/GB16/023 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: COBIMETINIB, INCLUDING A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF, IN PARTICULAR COBIMETINIB HEMIFUMARATE; REGISTERED: UK EU/1/15/1048/001(NI) 20151124; UK PLGB 00031/0849 20151124 |
| 1934174 | 122016000033 | Germany | ⤷ Sign Up | PRODUCT NAME: COBIMETINIB, OPTIONAL ALS PHARMAZEUTISCH ZULAESSIGES SALZ ODER SOLVAT DAVON, INSBESONDERE COBIMETINIB-HEMIFUMARAT; REGISTRATION NO/DATE: EU/1/15/1048 20151120 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
